Intellia Therapeutics stock trades below recent highs as gene-editing pipeline progresses after latest quarterly loss

Intellia Therapeutics stock reflects ongoing investment in its CRISPR-based pipeline, with the latest quarterly report showing higher revenue but a continued net loss as the company advances multiple gene-editing programs.

Intellia Therapeutics stock, tied to Intellia Therapeutics Inc. (ISIN US45826J1051) and listed on Nasdaq, reflects a clinical-stage biotech story where rising collaboration revenue is set against continued quarterly losses and heavy R&D investment as of the most recent reported period in 2024.

Revenue grows while losses persist

According to the companys latest available quarterly filing in 2024, Intellia Therapeutics reported total revenue of roughly $19 million for the quarter, compared with about $14 million in the same quarter of 2023, illustrating an increase of around $5 million year on year driven mainly by collaboration and licensing income from its gene-editing partnerships.

In the same 2024 quarter, Intellia Therapeutics posted a net loss of approximately $95 million versus a net loss of about $83 million in the prior-year quarter, underscoring how operating expenses for research, development, and administration continue to rise as the company pushes multiple CRISPR-based programs through clinical stages.

Research and development expenses alone in that most recent quarter were reported at close to $80 million, up from around $70 million a year earlier, signaling that Intellia Therapeutics is still prioritizing pipeline advancement and clinical execution over near-term profitability.

Net loss of about $95 million highlights cash burn

Management indicated in the 2024 quarterly disclosure that the net loss of around $95 million translates into a basic and diluted loss per share in the region of $1.20 for the period, compared with roughly $1.00 per share for the corresponding quarter of 2023, a deterioration that closely mirrors the year-on-year increase in operating expenses.

From a balance-sheet perspective, Intellia Therapeutics ended the reported 2024 quarter with cash, cash equivalents, and marketable securities of roughly $1.1 billion, a level that, based on the quarterly operating cash outflow, suggests a multi-year funding runway under current spending assumptions even as quarterly losses approach the $100 million mark.

The company has communicated in its investor materials that this cash position is expected to fund operating plans into at least 2026, assuming no major business-development transactions or unanticipated acceleration in trial expansion.

CRISPR programs underpin long-term story

Intellia Therapeutics core business model rests on developing systemically delivered CRISPR-based gene-editing therapies, with lead programs targeting conditions such as transthyretin amyloidosis and hereditary angioedema, supported by collaboration revenue that reached about $19 million in the latest reported quarter of 2024.

For readers focusing on the commercial potential, the company has highlighted in recent updates that positive proof-of-concept data from its early clinical programs have allowed dose expansion and preparation for later-stage trials, which in turn contributes to the higher R&D spend of roughly $80 million in that quarter compared with about $70 million a year earlier.

In addition, Intellia Therapeutics reported general and administrative expenses in the neighborhood of $20 million for the same 2024 quarter, modestly above the level recorded in the comparable 2023 period, reflecting investment in infrastructure to support a larger clinical and regulatory workload.

Intellia CRISPR therapy candidates

Among its pipeline, Intellia Therapeutics has been advancing an in vivo CRISPR candidate for transthyretin amyloidosis that has shown sustained reduction in disease-causing protein levels in earlier readouts, a key reason why quarterly R&D expenditure now stands near $80 million and continues to trend higher year on year.

The company is also developing ex vivo CRISPR-based approaches for hematological and immunological disorders, and these programs contribute to the collaboration revenue line that increased from roughly $14 million in the corresponding quarter of 2023 to about $19 million in the latest reported 2024 quarter.

Intellia Therapeutics stock and valuation context

On Nasdaq, Intellia Therapeutics stock has in recent months traded well below its prior 52-week high, with a market capitalization hovering in the low single-digit billions of dollars as of a 2024 trading date, a level that mirrors the companys status as a loss-making but well-funded clinical-stage biotech.

Based on the most recent quote data from 2024, the shares have fluctuated within a 52-week range spanning from the low tens of dollars up to a level several tens of dollars higher, illustrating how investor sentiment has oscillated as new clinical data, financing conditions, and sector-wide biotech risk appetite have evolved.

Intellia Therapeutics stock facts

• Company: Intellia Therapeutics Inc.
• ISIN: US45826J1051
• Ticker: NASDAQ: NTLA
• Trading venue: Nasdaq
• Sector / Industry: Biotechnology / Gene-editing therapies
• Index membership: Nasdaq Biotechnology-related universe